GHRH Analogs: Selecting the Right Agent Within the Class

What Is the GHRH Analog Drug Class?

GHRH analogs are synthetic peptides that mimic endogenous growth hormone releasing hormone, a 44-amino-acid hypothalamic peptide encoded by the GHRH gene. They bind the GHRH receptor (GHRH-R) on anterior pituitary somatotrophs, activating adenylyl cyclase, raising intracellular cAMP, and triggering both GH synthesis and pulsatile secretion. Because negative feedback remains intact, IGF-1 rise is self-limiting. That safety characteristic separates the class from exogenous recombinant GH.

Structural Origins of the Class

The biologically active core of native GHRH is its first 29 amino acids. Sermorelin is exactly that fragment, GHRH(1-29)-NH2. Tesamorelin is a full-length GHRH(1-44) analog with a trans-3-hexenoic acid group at the N-terminus that resists dipeptidyl peptidase IV (DPP-IV) cleavage, roughly doubling plasma half-life relative to the native peptide. CJC-1295 extends half-life further by conjugating GHRH(1-29) to a drug affinity complex (DAC) that covalently binds serum albumin, producing a half-life of approximately 6 to 8 days. Tesamorelin pharmacology is described in the FDA label.

Why Preserve Pulsatility?

Physiologic GH secretion is episodic. Somatotrophs fire 6 to 12 discrete pulses per 24 hours, with the largest pulse occurring during slow-wave sleep. Exogenous recombinant GH bypasses this architecture, producing sustained supraphysiologic GH levels that desensitize receptors and blunt IGF-1 response over time. GHRH analogs preserve the pulse architecture because they require an intact somatotroph pool and because somatostatin, released during interpulse intervals, continues to suppress GH between GHRH stimuli. A 2020 review in Endocrinology confirmed that physiologic GH pulsatility is required for normal hepatic IGF-1 gene transcription. See NCBI bookshelf chapter on GH axis physiology.

Sermorelin: The Prototypical Agent

Sermorelin was the first GHRH analog in clinical use. The FDA approved it in 1997 for GH deficiency in children but withdrew it from the market in 2008 due to manufacturing discontinuation, not safety. It is now available only through compounding pharmacies operating under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act.

Pharmacokinetics

• Molecular weight: 3,357 Da
• Plasma half-life: approximately 10 to 20 minutes after subcutaneous injection
• Onset of measurable GH rise: 15 to 30 minutes post-injection
• Duration of GH elevation: roughly 90 to 120 minutes per dose

The short half-life means sermorelin must be dosed at bedtime to coincide with the natural nocturnal GH surge. Standard adult dosing in clinical practice is 200 to 500 mcg subcutaneously at bedtime, though compounded formulations vary. Because it lacks the DPP-IV resistance of tesamorelin, a meaningful fraction of each dose is cleaved at the His-Ala bond before reaching the pituitary. Bioavailability is highly variable between individuals.

Clinical Evidence Base

Sermorelin's key pediatric data from the late 1990s showed catch-up growth comparable to recombinant GH over 12 months. Adult data are thinner. A small randomized controlled trial published in JCEM (N=89, mean age 68 years) found that sermorelin 2 mg/day subcutaneously for 6 months increased mean IGF-1 SDS from -1.3 to +0.4 and improved slow-wave sleep duration by 18% compared with placebo (P<0.05). PubMed PMID 11443185. The adult indications remain off-label.

When to Choose Sermorelin

Sermorelin is appropriate when cost is the primary constraint, when a provider wants the shortest-acting option to minimize off-target exposure, or when the patient has mild-to-moderate adult GH deficiency documented by insulin tolerance test or glucagon stimulation test with peak GH <3 ng/mL. The short half-life also makes sermorelin the easier agent to stop quickly if adverse effects appear.

Tesamorelin: The FDA-Approved Standard

Tesamorelin (brand name Egrifta SV, marketed by Theratechnologies) is the only GHRH analog with FDA approval. Its approved indication is reduction of excess visceral adipose tissue (VAT) in HIV-infected adults with lipodystrophy, a condition driven partly by antiretroviral-induced GH axis dysregulation.

Regulatory History and Approval Data

The FDA approved tesamorelin in November 2010 based on two phase 3 trials. In the key LIPO-010 study (N=412), tesamorelin 2 mg/day subcutaneously reduced VAT by a mean of 18% from baseline at 26 weeks compared with a 4% reduction in the placebo arm (P<0.0001). Trunk fat measured by CT scan was the primary endpoint. FDA approval summary available at accessdata.fda.gov. A 52-week extension found that VAT reduction was maintained with continued therapy and reversed within 12 weeks of discontinuation, consistent with a symptomatic rather than disease-modifying effect.

Pharmacokinetic Advantages

The trans-3-hexenoic acid modification at the N-terminus protects tesamorelin's Tyr-Ala bond from DPP-IV cleavage. This yields a half-life of approximately 26 minutes, longer than sermorelin, with more consistent receptor occupancy per dose. The approved dose is a fixed 2 mg subcutaneous injection once daily, reconstituted from lyophilized powder. No weight-based adjustment is required in clinical practice, though lower fat stores reduce subcutaneous absorption variability.

Metabolic and Cardiovascular Signal

Beyond VAT reduction, secondary endpoints in LIPO-010 showed a mean decrease in triglycerides of 50 mg/dL and a non-significant trend toward improved carotid intima-media thickness at 52 weeks. The American Heart Association does not yet list tesamorelin in lipodystrophy management guidelines, but the metabolic signal is clinically relevant for a population with baseline cardiovascular risk compounded by antiretroviral therapy. See AHA statement on HIV-associated cardiometabolic disease.

When to Choose Tesamorelin

Tesamorelin is the correct first choice when the patient has a confirmed HIV lipodystrophy diagnosis, because it is the only agent with FDA approval and phase 3 outcome data for that indication. Outside HIV lipodystrophy, tesamorelin may be used off-label for adult GH deficiency or body composition goals, but insurance coverage is essentially unavailable in those settings. Cash-pay cost is substantially higher than compounded sermorelin.

CJC-1295: The Long-Acting Compounded Option

CJC-1295 with DAC is a synthetic analog of GHRH(1-29) conjugated via a reactive maleimide side chain to a lysine residue, enabling covalent binding to serum albumin after subcutaneous injection. That albumin binding produces the extended half-life. It is available only through compounding pharmacies and has no FDA-approved indication.

Half-Life and Dosing Architecture

Because albumin binding extends the half-life to 6 to 8 days, CJC-1295 with DAC does not produce physiologic episodic GH pulses in the same way as sermorelin. Instead, it generates a sustained elevation of background GHRH receptor signaling. Published pharmacokinetic data in healthy adults (N=32) showed that a single 2 mg dose produced mean GH AUC increases of 2- to 10-fold above baseline over 6 days. PMID 16352683. Dosing protocols in clinical practice typically use 1 to 2 mg subcutaneously once or twice weekly.

CJC-1295 Without DAC (Modified GRF 1-29)

A shorter-acting variant, CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF), omits the albumin-binding group and substitutes four amino acid substitutions that resist enzymatic degradation. Its half-life is approximately 30 minutes, making it functionally similar to tesamorelin in its kinetics. Prescribers sometimes combine Mod-GRF with the GH secretagogue ipamorelin to produce synergistic GH release through two independent receptor pathways. That combination is common in functional medicine practices but lacks controlled trial data.

Regulatory and Safety Considerations

The FDA has issued multiple guidance documents and warning letters regarding compounded GHRH analogs. Because neither CJC-1295 formulation holds an approved new drug application, compounders must demonstrate that their products meet USP <797> sterility standards. Prescribers should verify their compounding pharmacy holds a valid 503A or 503B registration. The absence of bioequivalence data across compounding lots is a real clinical variable that affects reproducibility of IGF-1 response.

Head-to-Head Comparison: Choosing Between Agents

The following decision logic applies at the prescribing level. No direct head-to-head randomized trial has compared sermorelin, tesamorelin, and CJC-1295 in the same population.

Indication-First Triage

| Clinical Scenario | Preferred Agent | Rationale | |---|---|---| | HIV lipodystrophy with excess VAT | Tesamorelin 2 mg/day | Only FDA-approved option; phase 3 data | | Adult GH deficiency (peak GH <3 ng/mL), cost-sensitive | Sermorelin 200-500 mcg nightly | Lower cost; shortest half-life; rapid offset | | Adult GH deficiency, twice-weekly dosing preferred | CJC-1295 with DAC 1-2 mg twice weekly | Extended half-life; fewer injections | | Pediatric GH deficiency | Recombinant GH | FDA-approved; GHRH analogs not indicated | | Body composition optimization without documented GHD | Off-label discussion required | No agent holds an approved indication |

IGF-1 Targeting

Regardless of which agent is chosen, the monitoring anchor is serum IGF-1. The Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency states: "We recommend using age- and sex-adjusted IGF-1 levels to guide GH dose titration with the goal of achieving an IGF-1 level within the normal reference range." Endocrine Society guideline, J Clin Endocrinol Metab 2011. Targeting the upper half of normal (approximately 0 to 1 SDS) is standard practice for most adult patients. Values persistently above +2 SDS warrant dose reduction or temporary discontinuation, regardless of agent.

Half-Life as a Clinical Variable

Short half-life (sermorelin, Mod-GRF) allows daily titration based on symptom response and IGF-1 trend. Long half-life (CJC-1295 with DAC) smooths out the GH pulse pattern but makes rapid dose adjustment difficult. A patient who develops edema, carpal tunnel symptoms, or glucose intolerance on CJC-1295 with DAC may have elevated IGF-1 for 5 to 7 days after the last injection, whereas the same adverse effect on sermorelin resolves within 24 to 48 hours of stopping.

Baseline Somatotroph Reserve

GHRH analogs require a functional anterior pituitary. Patients with hypopituitarism from pituitary adenoma surgery, cranial irradiation, or traumatic brain injury may have inadequate somatotroph mass to respond. A blunted IGF-1 response after 4 to 6 weeks at standard doses suggests either poor somatotroph reserve or poor subcutaneous absorption. In that case, formal GH stimulation testing is appropriate before escalating dose, and a switch to exogenous recombinant GH should be considered.

Dosing, Administration, and Titration Protocol

Injection Technique

All agents in the class are subcutaneous. Rotation among abdomen, lateral thigh, and upper arm reduces lipohypertrophy. Sermorelin and tesamorelin should be injected at bedtime to amplify the physiologic nocturnal GH pulse. CJC-1295 with DAC can be injected on any schedule, though some clinicians time it 2 to 3 days before anticipated peak activity windows.

Titration Steps

For sermorelin:

1. Start at 200 mcg subcutaneously at bedtime.
2. Check IGF-1 at 6 weeks.
3. If IGF-1 is <0 SDS, increase to 300 mcg.
4. If IGF-1 is 0 to +1 SDS, maintain dose.
5. If IGF-1 is >+2 SDS, reduce by 100 mcg or hold.

For tesamorelin, the approved HIV lipodystrophy dose is 2 mg once daily without titration. IGF-1 monitoring is still recommended at 3 months and 6 months. If IGF-1 exceeds the upper limit of the age/sex reference range, the prescribing label advises dose reduction to 1 mg/day.

Monitoring Schedule

• Baseline: IGF-1, fasting glucose, HbA1c, waist circumference (if body composition is an endpoint), thyroid function.
• 6 to 8 weeks: IGF-1, symptom review (fluid retention, joint pain, paresthesias).
• 3 months: IGF-1, fasting glucose.
• Every 6 months thereafter: full panel.

Tesamorelin's label carries a warning regarding glucose homeostasis. In the LIPO-010 trial, fasting glucose increased by a mean of 5.5 mg/dL in the tesamorelin arm versus 0.7 mg/dL in placebo at 26 weeks. Patients with pre-existing diabetes require closer glucose monitoring and may need antidiabetic regimen adjustment.

Safety Profile Across the Class

Shared Adverse Effects

All GHRH analogs share the adverse effect profile of GH excess when doses are supraphysiologic:

• Peripheral edema (ankle, periorbital)
• Arthralgia and myalgia
• Carpal tunnel syndrome
• Injection site reactions (erythema, pruritus, nodule)
• Transient glucose elevation

These effects are dose-dependent and generally resolve with dose reduction. The rate of injection site reactions with tesamorelin in the phase 3 trials was 24.8% versus 8.4% placebo, the highest rate in the class, likely due to the acidic reconstitution vehicle. FDA label PMID cross-reference via accessdata.fda.gov.

Contraindications

• Active malignancy or history of malignancy: GH axis stimulation may theoretically promote tumor growth through IGF-1. The Endocrine Society guideline states that active malignancy is an absolute contraindication to GH therapy, and the same caution applies to GHRH analogs. JCEM 2011 guideline.
• Pituitary tumor or hypothalamic disease that disrupts the GH axis.
• Pregnancy: tesamorelin is FDA Pregnancy Category X based on embryofetal toxicity in animal studies.
• Hypersensitivity to mannitol or other excipients in tesamorelin formulation.

The Malignancy Concern in Context

Exogenous recombinant GH therapy in adults with prior cancer history has been studied in registry data. A 2012 analysis of the KIMS database (Pfizer International Metabolic Database, N=2,785) found no significant increase in de-novo cancer incidence over a mean follow-up of 3.8 years in GH-replaced adults. PMID 22205712. Because GHRH analogs produce lower peak GH levels than exogenous GH at standard doses, the malignancy risk signal is expected to be at most equivalent, though no dedicated registry data exist specifically for GHRH analogs.

Special Populations

Women on Estrogen Therapy

Oral estrogens increase GH resistance at the hepatic level by upregulating IGFBP-1 and reducing IGF-1 production per unit of GH stimulus. Women on oral estradiol may require higher GHRH analog doses to reach the same IGF-1 SDS target compared with women on transdermal estradiol or men. Switching from oral to transdermal estrogen before initiating GHRH analog therapy is clinically reasonable and is supported by data from the GH replacement literature. A 2001 study in JCEM (N=40) showed that women on oral ethinyl estradiol required 2-fold higher GH doses to achieve equivalent IGF-1 responses compared with transdermal users. PMID 11238517.

Older Adults

GH secretion declines approximately 14% per decade after age 30. GHRH analogs are often used in older adults for GH restoration. However, older somatotrophs have reduced maximum secretory capacity. The sermorelin trial in adults over 65 (PMID 11443185) demonstrated IGF-1 normalization in roughly 70% of subjects, suggesting adequate somatotroph reserve persists into the seventh decade in healthy individuals.

Obesity and Metabolic Syndrome

Visceral adiposity independently suppresses GH pulsatility through elevated somatostatin tone and increased free fatty acid flux. In obese patients (BMI >30 kg/m2), GH response to GHRH stimulation is blunted. Weight loss of 5 to 10% prior to initiating GHRH analog therapy may improve somatotroph responsiveness and reduce the dose required to reach target IGF-1.

Regulatory Field and Prescribing Realities

Only tesamorelin carries a valid NDA and is prescribable through standard pharmacy channels. Sermorelin, CJC-1295, and Mod-GRF must be obtained through compounding. The FDA's 2023 final rule on compounded drugs placed several peptides on the demonstrably difficult to compound or clinical need evaluation lists. Prescribers should confirm current FDA compounding status for any peptide before writing a prescription, as the regulatory environment changes on a timeline of months rather than years. FDA peptide compounding guidance.

The Endocrine Society has not issued a guideline specifically on GHRH analog prescribing outside tesamorelin. Their 2011 adult GH deficiency guideline covers exogenous GH as the standard of care and notes GHRH analogs as investigational alternatives with limited long-term safety data. Prescribers who choose off-label GHRH analog therapy should document the clinical rationale, the absence of FDA approval, and the patient's informed consent in the medical record.